Evidence map›Paper›PMID 40792551›Full record

ArticleBrain and behavior2025

Age: A Moderating Effect on Cerebrospinal Fluid Fibroblast Growth Factor 21 and Cognitive Function.

Ligang Shan, Ying Tao, Jiubo Fan, Yuyu Zhou, Danyang Zhao, Yanlong Liu, Xiaoli Han, Suriyakala Perumal Chandran, Fan Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ligang ShanDepartment of Anesthesiology, The Second Affiliated Hospital of Xiamen Medical College, Xiamen, China.
Ying TaoMedical Neurobiology Lab, Inner Mongolia Medical University, Hohhot, China.
Jiubo FanXiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China.
Yuyu ZhouMedical Neurobiology Lab, Inner Mongolia Medical University, Hohhot, China.
Danyang ZhaoMedical Neurobiology Lab, Inner Mongolia Medical University, Hohhot, China.
Yanlong LiuSchool of Mental Health, Wenzhou Medical University, Wenzhou, China.ORCID https://orcid.org/0000-0001-8733-8028
Xiaoli HanClinical Nutrition Department, Friendship Hospital of Urumqi in Xinjiang, Urumqi, China.
Suriyakala Perumal ChandranFaculty of Medicine, Lincoln University College, Petaling Jaya, Malaysia.
Fan WangBeijing Hui-Long-Guan Hospital, Peking University, Beijing, China.ORCID https://orcid.org/0000-0002-7048-8166

Funding

Beijing Natural Science Foundation 7152074Inner Mongolia Medical University Youth Cultivation Project YKD2021QN026Natural Science Foundation of China 81560229Natural Science Foundation of Fujian Province 2022J011393Natural Science Foundation of Inner Mongolia 2016D01A022Natural Science Foundation of Inner Mongolia 2022MS08068Natural Science Foundation of Inner Mongolia 2024QN08079Natural Science Foundation of Xinjiang Province 2018D01C228the 10th Inner Mongolia Autonomous Region 'Prairie excellence' Projectthe "Qingmiao" program of Beijing Municipal Hospital Management Center QML20212003the Technology Support Project of Xinjiang 2017E0267Urumqi Municipal Health Commission Science and Technology Plan Project 202236Xinjiang Outstanding Youth Science Grant 2017Q007Youth project of Inner Mongolia Medical University YKD2024QN012
6 · The paper itself

Abstract

backgroundFibroblast growth factors(FGF)19 subclass related to endocrine metabolism, including FGF19, FGF21, and FGF23, which is associated with cognition. Age can affect its secretion and has been identified as a significant risk factor for cognitive decline. Consequently, age may moderate the impact of the FGF19 subclass on cognitive function. This study aimed to investigate the association among the FGF19 subclass in cerebrospinal fluid (CSF), cognition, and age and further explore the moderating effects of age on cognitive changes related to the FGF19 subclass.

methodsIn this cross-sectional study, participants were stratified into two groups based on age, namely the ≤34 year old (n = 128) and >34 year old (n = 63) groups, and CSF FGF19 subclass levels were measured. Cognition was assessed using the Montreal Cognitive Assessment Scores.

resultsAge may play a moderating effect in the relationship between CSF FGF21 and cognition (R

conclusionsThis is the first study to report that age plays a moderating effect in the relationship between CSF FGF21 and cognition. Moreover, higher CSF FGF21 levels have a protective effect on cognition in individuals aged ≤34 years old. However, individuals aged>34 years old can improve cognition via alternative strategies.

Indexed as

AgingCognitionFibroblast Growth FactorsAdultAgedAge FactorsCognitive DysfunctionCross-Sectional StudiesFemaleFibroblast Growth Factor-23HumansMaleMiddle AgedYoung AdultFGF19 protein, humanFGF23 protein, humanFibroblast Growth Factor-23Fibroblast Growth Factorsagecerebrospinal fluidcognitionfibroblast growth factor 21moderation

Identifiers

PMID40792551
PMCPMC12340712

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.